Clinical evidence and review systems
Evidence holds longer. Clinical review gets a faster lane.
Roche extends Phase III follow-up for vamikibart while AnX examines documented review-time results from separate FDA submissions.
JobReports original SVG editorial illustration
2
verified developments
5
public employer boards refreshed
5
current openings curated
24h
news window to 10:30 AM ET
Editorial counts only. The job shortlist comes from five named public employer boards and is not a national inventory or market-wide hiring measure.
Ophthalmology / Phase III follow-up
Roche reports one-year follow-up from two vamikibart trials
Roche released 52-week results from the parallel Phase III MEERKAT and SANDCAT studies in adults with uveitic macular edema. The company said visual-acuity and retinal-thickness improvements seen during the controlled 16-week period were maintained through one year, with roughly two-thirds of eligible participants requiring no additional treatment after week 16.
The studies compared two doses of intravitreal vamikibart with a sham procedure during the primary phase. Roche also said regulators in the United States, European Union, China and Japan have accepted filings; the U.S. decision is expected by July 2027. Acceptance starts review—it is not approval.
Why it matters
Longer follow-up and parallel regulatory reviews concentrate work around evidence interpretation, medical communication, safety surveillance and submission support. Those are durable operating needs, but the announcement does not establish a new hiring plan.
Capsule endoscopy / AI-assisted review
AnX highlights review-time evidence documented in FDA submissions
AnX Robotica summarized reader-study results for its NaviCam ProScan system and a separately cleared capsule-endoscopy product. The company pointed to FDA documents showing shorter average small-bowel review times when each system's assistive workflow was used.
The studies used different designs and populations, so their percentages are not a head-to-head product comparison. Both systems assist clinicians rather than replace their judgment. The practical signal is continuing work in regulated clinical software, reader validation and workflow integration—not proof that one platform is superior or that faster review alone improves patient outcomes.
Public-board shortlist
Five current roles worth a closer look
These openings were visibly checked on their employers' application pages before publication. They are independent of the news above; no direct connection between an announcement and a listed role has been established.
Associate Director, Scientific Communications
Waltham, Massachusetts
Manager, Manufacturing Operations
Philadelphia, Pennsylvania
Clinical Trial Associate
Waltham, Massachusetts
Manufacturing Associate - Kitting (Temp)
Portland, Oregon
Senior Scientist, Computational Biology
Somerville, Massachusetts
Practical takeaway
Evidence stewardship is part of the product.
Today's two developments sit at different points in regulated development, yet both depend on teams that can turn complex data into defensible decisions. The five openings provide a separate, current view of work across communications, cell-therapy manufacturing, clinical operations, DNA production and computational biology within a deliberately bounded sample.
Explore previous briefings